SMN2 and proximal spinal muscular atrophy: Currently, pre-symptomatic SMA clinical trials are based on SMN target mechanisms, such as antisense oligonucleotide and small molecules that modify the splicing of the SMN2 pre-mRNA, and gene replacement therapy [43].